PACB — Stock Film
STOCK FILMSCENE 1/11PACB · $1.39
Stock Expert AI presents
PACB
Pacific Biosciences of California, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Pacific Biosciences of California, Inc. A quick introduction.

On the stock market since 2010, it operates in the world of health and science. It has 485 employees. Now — the numbers.

on the stock market since 2010
485 employees
$430.2M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $4.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$0
DEBT: $759.5M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 7 did the company clear?
7 / 7
EXPECTATIONS MET OR BEATEN
7
Nov 2024
Feb 2025
May 2025
Aug 2025
Nov 2025
Feb 2026
May 2026
7 TIMES IN THE LAST 7 QUARTERS
It clears the bar, quarter after quarter.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
20
very weak

Clearly below the class average.

FINANCIAL STRENGTH
28
very weak

Clearly below the class average.

VALUATION
27
very weak

Clearly below the class average.

GROWTH
31
very weak

Clearly below the class average.

PRICE MOMENTUM
29
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $160.0M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Delivers on expectations

It met or beat analyst expectations in 7 of the last 7 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $546.4M against $160.0M in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PACB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PACB is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 28, 2026 · stockexpertai.com · Stock Film